Understand the source comparison
KPV Protocol Comparison: Subcutaneous vs Oral Administration
Bioavailability 85–92% systemic absorption 15–22% systemic, 3–4× higher local mucosal concentration Subcutaneous for systemic inflammation; oral for mucosal repair Standard Dose 500–1000mcg daily 1500–2500mcg daily Oral requires 3–5× higher dose to match syste
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Bioavailability
- 85–92% systemic absorption
- 15–22% systemic, 3–4× higher local mucosal concentration
- Subcutaneous for systemic inflammation; oral for mucosal repair
- Standard Dose
- 500–1000mcg daily
- 1500–2500mcg daily
- Oral requires 3–5× higher dose to match systemic effect
- Onset to Effect
- 60–90 minutes to peak plasma
- 30–45 minutes to mucosal contact, slower systemic rise
- Oral acts faster locally but slower systemically
- Duration of Action
- 4–6 hours circulating half-life
- 20–30 minutes mucosal exposure before degradation
- Subcutaneous provides longer systemic coverage
- Ease of Use
- Requires sterile injection technique
- Simple oral consumption
- Oral avoids injection skill requirement
- Professional Assessment
- Use subcutaneous for Crohn's, UC, systemic gut inflammation. Use oral for leaky gut, localised enteritis, food sensitivity protocols. Split-dose protocols (subcutaneous AM, oral PM) may offer additive benefit but lack published trial data.